• PRINT  | 

NIH statement on the vitamin component of the Trial to Assess Chelation Therapy

Embargoed for Release:
March 10, 2013, 2:39 PM EDT

National Heart, Lung, and Blood Institute (NHLBI) Director Gary H. Gibbons, M.D.

Preliminary results from the vitamin component of the Trial to Assess Chelation Therapy (TACT) were released today during the American College of Cardiology’s 2013 Scientific Sessions. The study found that overall heart attack patients given a combination of high-dose oral vitamins and minerals did not exhibit a significant reduction in recurrent cardiac events over those who did not receive the high-dose vitamins and minerals. However, patients who received both high dose vitamins and active chelation compared to the placebo of both appeared to have some additional benefit. Further research is needed to understand fully the results.

Preliminary results from the chelation study were released on November 4 at the American Heart Association’s 2012 Scientific Sessions. The trial results suggested that chelation treatment, with or without supplements, provided a modest reduction in cardiac events (defined as recurrent heart attack, stroke, coronary revascularization, hospitalization for angina, or death) compared to a placebo treatment.

Because both study manuscripts currently are under peer review, NHLBI will refrain from further comment on any results until publication.

NHLBI appreciates the dedication of the researchers that carried out the trial and thanks the individuals who enrolled in it.

The TACT study is co-sponsored by NHLBI and the National Center for Complementary and Alternative Medicine.